WebMar 18, 2024 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx®-SCC (the Company’s 40-gene expression profile (GEP) test) can … WebMar 16, 2024 · T he stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five...
Castle Biosciences Inc. - MarketWatch
WebMar 30, 2024 · On average, analysts give the stock a Strong Buy rating. The average price target is $84, which means analysts expect the stock to climb by 35.51% over the next twelve months. That average ranking earns the stock an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver. WebApr 12, 2024 · Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to … sharp mx 2614n scan to pc
CSTL 22.32 -2.09 -8.56% : CASTLE BIOSCIENCES, INC. - MSN Money
WebCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Fr... Web18 hours ago · Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates 11/02/22-5:15PM EST Zacks Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales 10/28/22-11:51AM EST Zacks More... WebFeb 14, 2024 · Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative... 14/04/2024 05:58:20 Cookie Policy +44 (0) 203 8794 460 Free Membership Login porky\u0027s north shields